## CORRECTION



## Correction to: Use of antibiotics in the early COVID-19 pandemic in Poland, the Netherlands and Spain, from erraticism to (more) logic

Aleksandra Opalska<sup>1,8</sup> · Helga Gardarsdottir<sup>1,2</sup> · Marcel Kwa<sup>3</sup> · Jadwiga Wójkowska-Mach<sup>4</sup> · Monica Sabate<sup>5,6</sup> · Maria Elena Ballarin<sup>5,6</sup> · Mark de Groot<sup>7</sup> · Hubert Leufkens<sup>1</sup>

Published online: 22 August 2024 © The Author(s) 2024

## Correction to: European Journal of Clinical Pharmacology https://doi.org/10.1007/s00228-024-03726-1

The text should be inserted in the Acknowledgments section:

Jadwiga Wójkowska-Mach was supported by a grant from the the National Centre for Research and Development through the initiative "Support for specialist hospitals in fighting the spread of SARS-CoV-2 infection and in treating COVID-19" (contract number: SZPITALE-JEDNOIMIENNE/18/2020).

The original article has been corrected.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at https://doi.org/10.1007/ s00228-024-03726-1.

Hubert Leufkens h.g.m.leufkens@uu.nl

- <sup>1</sup> Division Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands
- <sup>2</sup> Department of Clinical Pharmacy, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, Netherlands
- <sup>3</sup> Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, Netherlands
- <sup>4</sup> Department of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Crakow, Poland

- <sup>5</sup> Department of Clinical Pharmacology, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
- <sup>6</sup> Clinical Pharmacology Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Barcelona, Spain
- <sup>7</sup> UPOD, Central Diagnostic Laboratory, Division Laboratories, Pharmacy and Biomedical Genetics, Utrecht, Netherlands
- <sup>8</sup> Directorate-General for Health and Food Safety, European Commission, Brussels, Belgium